Post-Marketing Safety Assessment of CAR T-Cell Therapies: Analysis of Individual Case Safety Reports in the VigiBase

被引：0
|
作者：
Alrasheed, Meshael [1 ]
Alhawas, Solaiman [1 ]
Alorf, Nora S. [2 ]
Al-Fadel, Nouf [3 ]
Alharbi, Fawaz [3 ]
机构：
[1] Saudi Food & Drug Author SFDA, Riyadh, Saudi Arabia
[2] Saudi Food & Drug Author, Riyadh, Saudi Arabia
[3] Saudi Food & Drug Author, Drug Sect, Drug Safety & Risk Management Dept, Execut Directorate Pharmacovigilance, Riyadh, Saudi Arabia
来源：
PHARMACOEPIDEMIOLOGY AND DRUG SAFETY | 2024年 / 33卷
关键词：
D O I：
暂无
中图分类号：
R1 [预防医学、卫生学];
学科分类号：
1004 ; 120402 ;
摘要：
1185
引用
收藏
页码：533 / 534
页数：2
相关论文
共 50 条
  • [41] Post-marketing safety evaluation of lurbinectedin: a pharmacovigilance analysis based on the FAERS database
    Li, Zhao
    Guo, Changying
    Liu, Xingfei
    Qiu, Zhengzhou
    Zhang, Ruilin
    FRONTIERS IN PHARMACOLOGY, 2024, 15
  • [42] Nonclinical safety assessment of engineered T cell therapies
    Lebrec, Herve
    Maier, Curtis C.
    Maki, Kazushige
    Ponce, Rafael
    Shenton, Jacintha
    Green, Shon
    REGULATORY TOXICOLOGY AND PHARMACOLOGY, 2021, 127
  • [43] Post-Marketing Safety Concerns with Esketamine: A Disproportionality Analysis of Spontaneous Reports Submitted to the FDA Adverse Event Reporting System
    Gastaldon, Chiara
    Raschi, Emanuel
    Kane, John M.
    Barbui, Corrado
    Schoretsanitis, Georgios
    PSYCHOTHERAPY AND PSYCHOSOMATICS, 2020, 90 (01) : 41 - 48
  • [44] New potential safety signals for CAR-T cell therapies
    Reactions Weekly, 2022, 1916 (1) : 10 - 10
  • [45] Post-marketing safety concerns with nirmatrelvir: A disproportionality analysis of spontaneous reports submitted to the FDA Adverse Event Reporting System
    Zhuang, Wei
    Xu, Jiabing
    Wu, Ye
    Yang, Jianhui
    Lin, Xiuxian
    Liao, Yufang
    Wan, Jun
    Weng, Lizhu
    Lin, Wanlong
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2023, 89 (09) : 2830 - 2842
  • [46] CAR T-cell therapies: Measuring the growing need for increasing long-term safety protocols
    Faroun, Yacoub
    Winkelman, Daniel F.
    Gambone, Nicholas
    Angelastro, Patrick
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [47] Efficacy and Safety of CAR T-cell Therapy for Plasma Cell Leukemia
    Gagelmann, Nico
    Dima, Danai
    Merz, Maximilan
    Ahmed, Nausheen
    Tovar, Natalia
    Oliver-Caldes, Aina
    Stoelzel, Friedrich
    Rathje, Kristin
    Fischer, Luise
    Platzbecker, Uwe
    Ayuk, Francis
    Anwer, Faiz
    Kfir-Ehrenfeld, Shlomit
    Asherie, Nathalie
    Assayag, Miri
    Mueller, Fabian
    Shune, Leyla
    Vucinik, Vladan
    Khouri, Jack
    McGuirk, Joseph
    Kroeger, Nicolaus
    Rodriguez-Lobato, Luis Gerardo
    Stepensky, Polina
    Abdallah, Al-Ola
    Fernandez de Larrea, Carlos
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 : S53 - S54
  • [48] FDA investigating safety risks in CAR T-cell recipients
    Nelson, Roxanne
    LANCET, 2023, 402 (10418): : 2181 - 2181
  • [49] Safety of CAR T-cell therapy in kidney transplant recipients
    Mamlouk, Omar
    Nair, Ranjit
    Iyer, Swaminathan P.
    Edwards, Angelina
    Neelapu, Sattva S.
    Steiner, Raphael E.
    Adkins, Sherry A.
    Hawkins, Misha
    Saini, Neeraj
    Devashish, Kartik
    Strati, Paolo
    Mandayam, Sreedhar
    Ahmed, Sairah
    BLOOD, 2021, 137 (18) : 2558 - 2562
  • [50] RNA Therapeutics for Improving CAR T-cell Safety and Efficacy
    Schaible, Philipp
    Bethge, Wolfgang
    Lengerke, Claudia
    Haraszti, Reka Agnes
    CANCER RESEARCH, 2023, 83 (03) : 354 - 362
12345